ClinicalTrials.gg
Not yet recruitingNCT06567808PICSUpdated Mar 12, 2026

Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial

A Phase 4 interventional study of Cefazolin and Vancomycin in Infection, Surgical Site, sponsored by Hamilton Health Sciences Corporation. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Hamilton Health Sciences Corporation · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
38,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing vancomycin in Surgical Wound Infection — 4 open to participants now, 5 under way, 1 of them phase 3. Vancomycin · Surgical Wound Infection.

Planned enrollment
Largest of 20
38,000 · median 329
Started
2026
with 1 other
Phase 4
9 of 20
3 open now
Registered
18th of 20
by date
Lead sponsor
1 of 20
Hamilton Health Sciences Corporation

Among the 20 studies testing vancomycin in Surgical Wound Infection, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 9 in phase 4, and was the 18th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

4 of the 20 studies testing vancomycin in Surgical Wound Infection are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About vancomycin

Vancomycin: first FDA approval 1964 (VANCOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing vancomycin in Surgical Wound Infection, or all of them as a file.
02

Study summary

The goal of this pragmatic, multi-centre factorial cluster randomized cross-over trial is to assess the efficacy of a combination of cefazolin plus vancomycin compared to cefazolin monotherapy, as well as a comparison of short versus long-term prophylaxis with four study arms: 1) cefazolin short-term, 2) cefazolin long-term, 3) cefazolin plus vancomycin short-term and 4) cefazolin plus vancomycin long-term.

Read the detailed description

Although antibiotic prophylaxis is considered the cornerstone of prevention for sternal surgical site infections (s-SSIs), the most effective antimicrobial regimen and optimal duration remain unclear. There is a pressing need to determine how best to prevent sternal surgical site infections and at the same time reduce adverse events from unnecessary antibiotic exposure. Currently, due to the lack of evidence, unproven approaches prevail and adherence to guidelines is poor. Rigorous randomized controlled trials data are needed for improved patient care.

A factorial cluster randomized cross-over trial, a design not used previously in this field, will address these gaps. To date, we have successfully enrolled close to 6,000 eligible patients in the vanguard study, and have shown that the trial as planned is feasible and operationally highly cost-effective.

03

Conditions studied

  • Infection, Surgical Site
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients (≥18 years of age) undergoing open-heart surgery (i.e. sternotomy, including minimally-invasive surgical techniques through mini-sternotomies)

Exclusion criteria

Exclusion Criteria:

  1. On systemic antibiotics or with an active bacterial infection at the time of surgery
  2. Previously enrolled in this trial
  3. Known to be colonized with methicillin-resistant staphylococcus aureus (MRSA). Where it is unethical to not administer glycopeptides.
  4. Beta-lactam or vancomycin allergy precluding the use of cefazolin or vancomycin, respectively
  5. Participation in other studies that may interfere with this trial.
  6. Patients undergoing cardiac transplant
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
38,000 participants (estimated)

Study arms

  • Experimental
    cefazolin short-term

    Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first).

    Drug: Cefazolin

  • Experimental
    cefazolin long-term

    Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first) and the five post-operative doses in the long-term arms will be 2g every 8 hours.

    Drug: Cefazolin

  • Experimental
    cefazolin plus vancomycin short-term

    Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first). Vancomycin will be dosed at roughly 15mg/kg body weight intravenously, i.e. 1g or 1.5g if greater than 85kg body weight and is to be administered within 60-90 minutes of the surgical procedure.

    Drug: Cefazolin · Drug: Vancomycin

  • Experimental
    cefazolin plus vancomycin long-term

    Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first) and the five post-operative doses in the long-term arms will be 2g every 8 hours. Vancomycin will be dosed at roughly 15mg/kg body weight intravenously, i.e. 1g or 1.5g if greater than 85kg body weight and is to be administered within 60-90 minutes of the surgical procedure. The same dose will be used for the 3 post-operative doses in the long-term arm.

    Drug: Cefazolin · Drug: Vancomycin

Interventions

  • administration as outlined

    Also known as: Kefzol, Ancef

  • administered as outlined

    Also known as: Vancocin, Firvanq

06

What researchers measure

Primary outcomes

  1. Deep incisional or organ/space (complex) sternal surgical site infection (CDC/NHSN)

    Sternal surgical site infections are defined by clinical and microbiological criteria of infection at the surgical site that are associated with the operative procedure occurring within 90 days after surgery.

    Time frame: 3 months post-surgery

Secondary outcomes

  1. All types of sternal surgical site infections (superficial, deep, organ; (CDC/NHSN)

    Sternal surgical site infections are defined by clinical and microbiological criteria of infection at the surgical site that are associated with the operative procedure occurring within 90 days after surgery.

    Time frame: 3 months post-surgery

  2. Clostridium difficile infection

    Laboratory confirmed

    Time frame: 3 months post-surgery

  3. Mortality

    Mortality in participants with an active infection

    Time frame: 3 months post-surgery

  4. Number of patients with acute kidney injury

    Acute kidney injury following the Acute Kidney Injury Network definition

    Time frame: 7 days post surgery

  5. Number of patients with sternal revision surgery

    For suspected sternal surgical site infection

    Time frame: 3 months post surgery

  6. Rate of antimicrobial resistant organisms causing sternal wound infections

    including relevant susceptibilities and stratified by study arm

    Time frame: 3 months post-surgery

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Apr 2028, 25 months later.

Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 25 months is below that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 23, 2024
StartEst.
Mar 1, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Jul 30, 2028
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06567808
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Mar 1, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Mar 12, 2026

Study contacts

Dominik Mertz, MD, MSc
Contact
mertz@hhsc.ca
905-521-2100 ext. 43952
Ingrid Copland
Contact
pics@phri.ca
Dominik Mertz, MD, MSc
principal investigator · Hamilton Health Sciences Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vancomycin

Start the discussion